(Q40070572)

English

Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression (English)

1 reference

Europe PubMed Central

17 September 2017

1 reference

based on heuristic

inferred from title

author name string

Xiu-Xian Wu

1

1 reference

Europe PubMed Central

17 September 2017

Xing-Hua Jin

2

1 reference

Europe PubMed Central

17 September 2017

Yu Zeng

3

1 reference

Europe PubMed Central

17 September 2017

Ahmed Mamdouh Abd El Hamed

4

1 reference

Europe PubMed Central

17 September 2017

Yoshiyuki Kakehi

5

1 reference

Europe PubMed Central

17 September 2017

publication date

8 October 2007

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

98

1 reference

Europe PubMed Central

17 September 2017

12

1 reference

Europe PubMed Central

17 September 2017

1969-1976

1 reference

Europe PubMed Central

17 September 2017

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Therapeutic applications of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Proteasome-dependent degradation of cyclin D1 in 1-methyl-4-phenylpyridinium ion (MPP+)-induced cell cycle arrest

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

APO2 ligand: a novel lethal weapon against malignant glioma?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Increased intracellular doxorubicin by anti-FAS monoclonal antibody: a mechanism that enhances the cytotoxicity in renal cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00632.X

21 January 2018

Identifiers

10.1111/J.1349-7006.2007.00632.X

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40070572&oldid=1883619454"